Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 29Neoplasms 14Breast Neoplasms 8Fallopian Tube Neoplasms 7Prostatic Neoplasms 4Neoplasm Metastasis 4Triple Negative Breast Neoplasms 2Prostatic Neoplasms, Castration-Resistant 2Melanoma 2Carcinoma, Ovarian Epithelial 2Carcinoma, Non-Small-Cell Lung 2Urologic Neoplasms 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Solid Tumor 1Small Cell Lung Carcinoma 1Recurrence 1Prostatic Diseases 1Pancreatic Neoplasms 1Ovarian Diseases 1Osteosarcoma 1Neuroblastoma 1Metastatic Castration-sensitive Prostate Cancer 1Metastatic Castration-resistant Prostate Cancer 1Lymphoma 1Lung Neoplasms 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hereditary Sensory and Autonomic Neuropathies 1

Interventions

Fulvestrant 9Alpelisib 6Letrozole 4serabelisib 3ribociclib 3palbociclib 3duvelisib 3berzosertib 3Paclitaxel 3PX-866 3Cetuximab 3sapanisertib 2pembrolizumab 2parsaclisib 2binimetinib 2Topotecan 2NVP-BKM120 2Irinotecan 2Gemcitabine 2venetoclax 1tipifarnib 1talazoparib 1sotorasib 1ruxolitinib 1olaparib 1obinutuzumab 1niraparib 1lorlatinib 1liposomal doxorubicin 1gedatolisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Hereditary Sensory and Autonomic Neuropathies × niraparib × Clear all
NCT06433219 2026-06-03

Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

EMD Serono

Phase 2 Active not recruiting
63 enrolled
Gynecologic

Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡